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Abstract
Background: Endothelial MAdCAM-1 (mucosal addressin cell adhesion molecule-1) expression is
associated with the oxidant-dependent induction and progress of inflammatory bowel disease
(IBD). Melatonin, a relatively safe, potent antioxidant, has shown efficacy in several chronic injury
models may limit MAdCAM-1 expression and therefore have a therapeutic use in IBD.
Methods: We examined how different doses of melatonin reduced endothelial MAdCAM-1
induced by TNF-a in an in vitro model of lymphatic endothelium. Endothelial monolayers were
pretreated with melatonin prior to, and during an exposure, to TNF-a (1 ng/ml, 24 h), and
MAdCAM-1 expression measured by immunoblotting.
Results: MAdCAM-1 was induced by TNF-a. Melatonin at concentrations over 100 µm (10-4 M)
significantly attenuated MAdCAM-1 expression and was maximal at 1 mM.
Conclusions: Our data indicate that melatonin may exert therapeutic activity in IBD through its
ability to inhibit NF-kB dependent induction of MAdCAM-1.
Background
It has been previously reported that the mucosal addressin
cell adhesion molecule-1 is expressed at high levels in gut
associated lymphoid tissue, and that its' expression is dra-
matically increased during active episodes of inflammato-
ry bowel disease (IBD), e.g. Crohns' colitis [1]. MAdCAM-
1 expressed on lymphatic endothelial cells serves as a lig-
and for a4b7 integrin expressing lymphocytes that allows
these cells to arrest and migrate within intestinal lymphat-
ics [2–5], and appears promote development of chronic
intestinal inflammatory states [1,5,6]. The role of the
MAdCAM-1/a4b7 couplet in injury is well supported by
studies which show that blockade of either component re-
duces the development of inflammation [5,6]. Therefore,
therapies to diminish the net expression of MAdCAM-1 in
response to the pro-inflammatory cytokines mobilized
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during inflammation is an important potential avenue for
research. We have previously described that several thera-
peutic agents which are currently used for IBD therapy
(dexamethasone, IL-10) attenuate MAdCAM-1 expression
and may explain part of the basis of therapy with these
agents [7]. Based on these results, we wished to determine
if melatonin could have a significant impact on the ex-
pression of MAdCAM-1 in lymphatic endothelial cells
that have been stimulated with TNF-a, and whether TNF-
a induced NF-kB activation in lymphatic endothelium is
reduced by MAdCAM-1.
Methods
Reagents
Mouse TNF-a was purchased from ENDOGEN
(Stoughton, MA).
Cell culture
SVEC4-10, an SV40 transformed lymphatic derived en-
dothelial cell line which expresses MAdCAM-1 in re-
sponse to TNF-a or IL-1b exposure [8] was maintained in
DMEM + 10% fetal calf serum +1% antibiotic/ antimy-
cotic. Cells were seeded at 20,000 cells/cm2; and used im-
mediately after reaching confluency.
Treatment protocol
SVEC 4–10 were pre-treated for 30 minutes with melaton-
in at 0.1, 0.5 and 1 mM, and then incubated in culture me-
dium for 24 with 1 ng/ml TNF-a. Samples were then
isolated in Laemmli sample buffer.
Western analysis of cell lysates
Western blotting was performed as described [3,7,9]. Pro-
tein concentration for loading was determined using the
BCA protein assay kit (Pierce, Rockland, IL). 75 ug of pro-
tein was loaded into each lane of 7.5% SDS/PAGE gels,
electrophoresed and blotted as described [9]. After elec-
troblotting, equal protein loading was confirmed by Pon-
ceau Red S staining. TNF-a did not alter the well-to-well
protein concentration measured by protein measurement
or Ponceau staining. Rat anti MadCAM-1 mAb (clone
MECA367) was purchased from Pharmingen (San Diego,
CA) [3]. Goat anti-rat HRP antibody (Sigma) was used as
2° Ab at a 1:2000 dilution. Blots were visualized on hyper-
film (KODAK) using enhanced chemiluminescence (ECL,
Amersham Life Sciences, Piscataway, NJ). Densitometric
analysis of MAdCAM-1 expression was determined using
Image Pro Plus™ (Media Cybernetics, Silver Springs, MD)
using a 256-shade gray scale. All experiments were repeat-
ed 3X.
Phospho-NF-kB p65 western analysis of cell lysates
To measure NF-kB activation, monolayers were either pre-
treated (1 h) with melatonin, and then co-treated with
TNF-a (30 min), or treated without test agents and co-
treated with TNF-a (30 min), or not treated (controls). All
samples were harvested at 30 min. 75 µg of protein from
each sample was separated on 7.5% SDS-PAGE gels and
transferred to nitrocellulose as described. Blots were
blocked with 5% milk powder in PBS + 0.1%Tween-20 at
room temperature for 2 h, washed twice for 10 min with
wash buffer (0.1% Tween-20 in PBS). 1° rabbit anti-phos-
pho-NF-kB p65 polyclonal (Ser536) Ab (Cell Signaling
Technology, MA) was added at a concentration of 1 µg/ml
and incubated overnight at 4°C. These membranes were
washed twice with wash buffer. 2° goat anti-rabbit horse-
radish peroxidase-conjugated secondary antibody (Sig-
ma) was added at a 1:2000 dilution for 2 h. Lastly,
membranes were washed 3 times and developed using en-
hanced chemiluminescence (ECL) (Amersham, La Jolla,
CA). The density of phospho-NF-kB p65 staining was
measured by scanning the 65 kD band, using a HP Scan-
Jet™ flatbed scanner. Images were analyzed for density us-
ing Image Pro Plus™ image analysis software (Media
Cybernetics, Silver Springs, MD). The data are expressed
as a percentage of TNF-a-induced level of density (set as
100% or maximum).
Results
TNF-a (1 ng/ml) significantly increased the expression of
MAdCAM-1 compared to untreated controls (fig. 1). At 1
ng/ml densitometry indicates that the expression of MAd-
CAM-1 was increased in SVEC 4–10 cells by over 5-fold at
24 hours. This represents approximately 30% of the max-
imal expression observed when cells are exposed to 20 ng/
ml TNF-a [15]. The addition of melatonin to these cul-
tures prior to, and during exposure to TNF-a significantly
reduced the expression of MAdCAM-1. Melatonin at 100
µM, 500 µM and 1000 µM significantly reduced respon-
siveness to TNF-a (measured by induction of MAdCAM-
1). Lower doses of melatonin (50 µM) produced slight but
statistically insignificant changes in MAdCAM-1 expres-
sion. We also found that melatonin (500 µM) also signif-
icantly reduced the activation of NF-kB as measured by
the phosphorylation of the NF-kB p65 subunit. TNF-a (30
min, 1 ng/ml) significantly increased phosphorylation of
the p65 subunit of NF-kB (fig. 2). Pre-treatment with 500
µM melatonin significantly decreased the expression of
MAdCAM-1 (compared to TNF-a alone), although this
level was still slightly, but significantly elevated compared
to untreated controls. TNF-a at this concentration is not
wholly specific for MAdCAM-1, other adhesion mole-
cules, e.g. VCAM-1 and ICAM-1 are also similarly mobi-
lized by this concentration of TNF-a (data not shown),
while the total cell protein is unaltered.BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/9
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Discussion
MAdCAM-1 is an endothelial cell surface molecule selec-
tively expressed on 'high' endothelium that is required for
lymphocyte homing to lymphatic vessels, especially to
gut-associated lymphoid tissues [1,2,10–14]. Interactions
mediated by MAdCAM-1 and its receptor, α 4β 7, mediate
lymphocyte homing to the intestine which initiates and
sustains gut inflammation in inflammatory bowel disease
(IBD). This notion is well-supported by studies demon-
strating that antibodies against either MAdCAM-1 or the
MAdCAM-1 ligand, β 7-integrin, block lymphocyte re-
cruitment to the inflamed colon, and will reduce experi-
mental IBD [5,6]. Therefore, interference with either
MAdCAM-1 binding or the net expression of MAdCAM-1
may be beneficial in IBD therapy. Here we showed that an
endogenous, relatively safe and well tolerated antioxi-
dant, melatonin, attenuated MAdCAM-1 expression in re-
sponse to TNF-a.. The level of protection provided by
100–1000  µM melatonin was comparable to that ob-
tained with high doses of IL-10 or dexamethasone that we
described in a previous in vitro study [9]. It is worth noting
that TNF-a does not specifically mobilize only MAdCAM-
1, nor does melatonin inhibit expression of only MAd-
CAM-1. TNF-a will also induce other ECAMs like ICAM-1
and VCAM-1 [22], and melatonin will also inhibit the ex-
pression of ICAM-1 and P-selectin [20]. Therefore, we can-
not exclude possible additional contributions made by
these adhesive systems in the beneficial effect of melaton-
in in chronic inflammation.
Several studies support the effectiveness of antioxidants as
a means to limit the excessive expression of many types of
endothelial cell adhesion molecules in inflammation, in-
cluding that of MAdCAM-1. Melatonin is a pineal hor-
Figure 1
Melatonin significantly attenuates TNF-a induced MAdCAM-1 Expression. Figure 1 shows the induction of MAd-
CAM-1 by TNF-a (1 ng/ml), and its inhibition by increasing concentrations of melatonin (0.1, 0.5 and 1 mM). * = significantly dif-
ferent (p < 0.05) from control.BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/9
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mone that has recently been proposed as a relatively safe
and well-tolerated regulator of circadian rhythm [16],
with strong antioxidant properties [17]. As a potent anti-
oxidant, melatonin has been used in several chronic inju-
ry models with good success. For example, 0.7 mg/kg
inhibits TNF-a induced hypotension through blockade of
NO synthase activity in cancer patients [18]. In murine
and rat models of colitis, melatonin also blocked several
indices of gut injury in chemically induced models of col-
itis [19–21]. The basis of the protective effects of antioxi-
dants in all of these models is consistent with interference
with the NF-kB transcriptional system [22], which drives
the expression of several genes activated during inflamma-
tion, particularly those of adhesion molecules like MAd-
CAM-1 [9,22]. In support of this, we have previously
demonstrated that MAdCAM-1 expression is mediated at
least partially through NF-kB [9]. Gilad et al. (1998) have
also demonstrated that melatonin will inhibit the NF-kB
system [23].
We found here that 500 µM melatonin significantly re-
duced TNF-a induced activation of NF-kB, consistent with
these previous findings. Melatonin also decreases the re-
lease of cytokines. Administration of melatonin signifi-
cantly reduced TNF-a levels in humans with neoplasms
[18]. Therefore, in vivo, melatonin could also prevent the
development of chronic gut injury by blocking synthesis
and responses to the cytokines that drive the expression of
adhesion molecules like MAdCAM-1. Melatonin and me-
latonin binding sites are found highly concentrated with-
in the intestine, and concentrations in the gut are between
10–100 times that found in the plasma [24]. Further, it
has been suggested that the intestine is the major site for
extra-pineal melatonin activity in the gut, particularly the
Figure 2
Melatonin prevents TNF-a induced phosphorylation of NF-kB p65. Figure 2 shows that the phosphorylation of NF-kB
p65 induced by 1 ng/ml TNF-a is significantly attenuated by 0.5 mM melatonin. * = significantly different (p < 0.05) from TNF-a,
# = p < 0.05 from control.BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/9
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lymphatics [24]. Therefore, melatonin may play an im-
portant role in regulation of the intestine, but it is not yet
clear whether a possible melatonin deficiency may play
any role in the etiology of IBD.
Further, and importantly, although melatonin decreased
the expression of MAdCAM-1 in this study, the introduc-
tion of melatonin into the treatment of human IBD
should be cautiously approached. The doses of melatonin
used in our study represent from 5–50 times the dose that
is used as an over the counter sleep aid (3 mg). Therefore,
the effects of relatively high doses of melatonin in hu-
mans should not be considered to be without the possibil-
ity for harm or toxicity. A careful evaluation of high doses
of melatonin in clinical studies will be needed before it
can be safely introduced into a regimen for therapy.
Conclusions
Our study shows that endothelial MAdCAM-1 expression
is increased by TNF-a, and is dose-dependently inhibited
by melatonin. The data suggest that melatonin may there-
fore be of clinical value in therapy for inflammatory bow-
el disease through its ability to limit the expression of
adhesion molecules e.g. MAdCAM-1.
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